AUXILIUM PHARMACEUTICALS
WKN: A0B7E6 / ISIN: US05334D1072Auxilium Pharmaceuticals
26.06.14 14:03
#1
Capret
Auxilium Pharmaceuticals
http://auxilium.com/
About Auxilium
Auxilium is a fully integrated specialty biopharmaceutical company focused on developing and marketing products to predominantly specialist audiences. Auxilium means "assistance" in Latin, and that"s a fitting description for all of our biopharmaceutical development and commercialization efforts.
Auxilium Pharmaceuticals—Dedicated to innovations for life
Although we are living in an era of rapid advances in medical technology, many of society"s medical concerns remain unaddressed. Auxilium works to address some of these unmet needs.
By doing so, we work in important areas of the pharmaceutical industry that require forward thinking and novel solutions that promote better health and living.
Through advancement and expansion, Auxilium is dedicated to providing innovative solutions for underserved diseases that improve health and quality of life.
About Auxilium
Auxilium is a fully integrated specialty biopharmaceutical company focused on developing and marketing products to predominantly specialist audiences. Auxilium means "assistance" in Latin, and that"s a fitting description for all of our biopharmaceutical development and commercialization efforts.
Auxilium Pharmaceuticals—Dedicated to innovations for life
Although we are living in an era of rapid advances in medical technology, many of society"s medical concerns remain unaddressed. Auxilium works to address some of these unmet needs.
By doing so, we work in important areas of the pharmaceutical industry that require forward thinking and novel solutions that promote better health and living.
Through advancement and expansion, Auxilium is dedicated to providing innovative solutions for underserved diseases that improve health and quality of life.
09.10.14 12:49
#8
Capret
Endo To Acquire Auxilium
- Auxilium Shareholders to Receive $33.25 Per Share
- Combination Designed to Create Leading Specialty Healthcare Company with Expanded Platform for Future Growth
- Addition of Auxilium's Leading Men's Health Products and Development Portfolio Expected to Significantly Enhance Endo's Branded Pharmaceutical Business
- Transaction Expected to be Immediately Accretive
- Endo Expects to Generate up to $175 Million of Annual Run Rate Operating Expense Reductions Inclusive of the $75 Million of Reductions Previously Announced by Auxilium
- Combination Designed to Create Leading Specialty Healthcare Company with Expanded Platform for Future Growth
- Addition of Auxilium's Leading Men's Health Products and Development Portfolio Expected to Significantly Enhance Endo's Branded Pharmaceutical Business
- Transaction Expected to be Immediately Accretive
- Endo Expects to Generate up to $175 Million of Annual Run Rate Operating Expense Reductions Inclusive of the $75 Million of Reductions Previously Announced by Auxilium